Skip to main content

Table 3 Mortality rates of patients with eGFR ≥ 30 who received levosimendan versus dobutamine alone

From: Levosimendan use in patients with acute heart failure and reduced ejection fraction with or without severe renal dysfunction in critical cardiac care units: a multi-institution database study

Outcomes Event (%) Levosimendan vs. dobutamine
Levosimendan Dobutamine HR (95% CI) P value
Before PSM patient numbers 102 567   
 In-hospital mortality 13 (12.7) 61 (10.8) 0.80 (0.43–1.51) 0.491
 5-day mortality 3 (2.9) 19 (3.4) 0.87 (0.26–2.94) 0.822
 14-day mortality 7 (6.9) 38 (6.7) 1.004 (0.45–2.25) 0.992
 30-day mortality 13 (12.7) 57 (10.1) 1.23 (0.68–2.25) 0.496
 90-day mortality 20 (19.6) 83 (14.6) 1.31 (0.80–2.13) 0.285
 180-day mortality 22 (21.6) 99 (17.5) 1.20 (0.76–1.91) 0.438
After PSM patient numbers 82 145   
 In-hospital mortality 9 (11.0) 25 (17.2) 0.37 (0.15–0.92) 0.032
 5-day mortality 2 (2.4) 10 (6.9) 0.34 (0.07–1.60) 0.173
 14-day mortality 5 (6.1) 19 (13.1) 0.44 (0.17–1.14) 0.091
 30-day mortality 10 (12.2) 28 (19.3) 0.59 (0.28–1.23) 0.160
 90-day mortality 16 (19.5) 31 (21.4) 0.85 (0.45–1.60) 0.604
 180-day mortality 18 (22.0) 36 (24.8) 0.82 (0.46–1.46) 0.501
  1. HR hazard ratio, CI confidence interval, PSM propensity score matching